CN1814149A - Medicine composition for treating diabetes or diabetes kidney-disease, and preparing method - Google Patents
Medicine composition for treating diabetes or diabetes kidney-disease, and preparing method Download PDFInfo
- Publication number
- CN1814149A CN1814149A CN 200510110763 CN200510110763A CN1814149A CN 1814149 A CN1814149 A CN 1814149A CN 200510110763 CN200510110763 CN 200510110763 CN 200510110763 A CN200510110763 A CN 200510110763A CN 1814149 A CN1814149 A CN 1814149A
- Authority
- CN
- China
- Prior art keywords
- cortex
- extract
- content
- rhizoma anemarrhenae
- cortex cinnamomi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a drug combination for curing diabetes or nephropathy and the preparing method thereof. And it is prepared of extracts from Chinese drugs Amur Corktree Bark, Common Anemarrhena Rhizome and Cassia Bark as effective medicinal components and comprises Amur Corktree Bark alkaloid component, Common Anemarrhena Rhizome glucoside component, Cassia Bark naphtha and polyphenol component, where these extracts can be extracted from Amur Corktree Bark, Common Anemarrhena Rhizome and Cassia Bark, respectively and then mixed, and also extracted from Amur Corktree Bark, Common Anemarrhena Rhizome and Cassia Bark together. And the preparing method comprises the steps of alcoholic extraction, macroporous resin absorption, eluting, concentrating, drying, etc.
Description
Technical field
The invention belongs to pharmaceutical field, be specifically related to a kind of Chinese medicine active component compositions that is used for the treatment of diabetes or diabetic nephropathy.Be specially the pharmaceutical composition of Chinese medicine Cortex Phellodendri, the Rhizoma Anemarrhenae and cinnamomic active component compatibility.
Background technology
The World Health Organization's statistics for several years running shows that diabetes and complication thereof have become the difficult disease of the serious harm human health that is only second to cancer and cardiovascular and cerebrovascular disease.Remedies for diabetes mainly contains three major types at present: biological medicine insulin, chemical medicine sulfonylurea, biguanides and Chinese patent medicine class.Insulin preparation costs an arm and a leg, and is difficult to promote; Though chemistry medicine blood sugar reducing function is obvious, and is bigger to toxic and side effects such as liver, kidneys, also causes that cardiovascular complication increases the weight of easily etc.Though Chinese patent medicine has certain therapeutical effect, the prescription decoction that mostly is crude extract preparation or oneself plan of doctor of present clinical use, it is remarkable to lack drug effect, and the active ingredient and the mechanism of action are clear, and is quality controllable, dosage form advanced person's modern Chinese medicine.
Compound recipe by Cortex Phellodendri, the Rhizoma Anemarrhenae and Cortex Cinnamomi three flavor Chinese medicines are formed records the earliest in " secret record of the orchid chamber " of the Li Gao of the famous doctor family writing of China Jin Dynasty, claims on " ball of being open to the custom "." Pill for Replenishing the Kidney-yin " that " People's Republic of China's drug standard, first in Chinese traditional patent formulation preparation, WS3-B-0158-89 " records, it is identical with " ball of being open to the custom " to write out a prescription, and also is made up of Cortex Phellodendri, the Rhizoma Anemarrhenae and Cortex Cinnamomi.Ancient times and modern clinical this Chinese medicine compound is used for the treatment of stranguria, the difficulty in urination etc., accumulate bladder as heat, little distention and fullness in the abdomen, urine retention is obstructed.
In recent years, there is the research of Cortex Phellodendri, the Rhizoma Anemarrhenae and Cortex Cinnamomi single medical material and effective ingredient thereof treatment diabetes more.For example, " Acta Pharmacologica Sinica, 2004,25:496-502 " report, berberine can promote insulin secretion, regulates lipid metabolism and has the anti-diabetic effect; " the new traditional Chinese medical science, 1997,29 (3): 33-34 " report, berberine (berberine) is clinical to be 63.3% to type ii diabetes patient effective percentage, untoward reaction is little; " Exp Clin EndocrinolDiabetes, 2004,112:520-525 " report, Rhizoma Anemarrhenae ethanol extract can stimulate the diabetes rat excreting insulin and play hypoglycemic activity; " Chinese herbal medicine, 1996,17:605-606 " report, the polysaccharide composition in the Rhizoma Anemarrhenae can significantly reduce inductive blood glucose in diabetic mice of alloxan and liver glycogen; " Chinese Chinese medicine information magazine, 2001,8:26 " report, Cortex Cinnamomi volatile oil has the effect of tangible reduction blood glucose in diabetic mice.
Disclose Cortex Phellodendri, the Rhizoma Anemarrhenae and Cortex Cinnamomi and other medicines among the Chinese patent CN1127657A and made up the effect that the Jiangtang capsule of making has the treatment type ii diabetes; The Jiangtang capsule that Cortex Phellodendri, the Rhizoma Anemarrhenae, BIANGUI (being Cortex Cinnamomi) and other medicines combination are made is disclosed among the CN1259383A; The treatment diabetes ointment that Cortex Phellodendri, Cortex Cinnamomi and other medicines combination are made is disclosed among the CN1555817A; The Chinese medicine preparation of the treatment type 2 diabetes mellitus that Cortex Cinnamomi, the Rhizoma Anemarrhenae and other medicines combination make is disclosed among the CN1370585A; The health food that is suitable for diabetics that timosaponin and other other composition combination are made is disclosed among the CN1088748A; The effect that the Chinese medicine composition that contains berberine hydrochloride has the treatment diabetes of gastric heat type is disclosed among the CN1386527A; The dietetic therapy milk slice that is used for diabetes that the combination of cinnamic aldehyde and other composition is made is disclosed among the CN1498545A; CN1475222A discloses the preparation that the combination of anthocyanidin and other composition makes and has had hypoglycemic activity.
But, in above-mentioned documents, all openly do not have only the pharmaceutical preparation of the treatment diabetes that the extract of Cortex Phellodendri, the Rhizoma Anemarrhenae and three kinds of medical materials of Cortex Cinnamomi makes, do not have open with the volatile oil (cinnamic aldehyde) of composition and the pharmaceutical preparation that polyatomic phenol composition (procyanidin) compatible combination is made in the alkaloids composition (berberine) in the Cortex Phellodendri, glycoside composition (timosaponin, Chinonin) in the Rhizoma Anemarrhenae and the Cortex Cinnamomi yet.
Summary of the invention
The object of the present invention is to provide a kind of is the pharmaceutical composition of active drug with component compatibility by Chinese medicine Cortex Phellodendri, the Rhizoma Anemarrhenae and cinnamomic extract, is used for the treatment of diabetes or diabetic nephropathy.
In treatment diabetes provided by the invention or diabetic nephropathy drugs compositions, each active drug with the component extract to be equivalent to the used medical material weight ratio of its extraction is: 2 parts of Cortex Phellodendris, Rhizoma Anemarrhenae 1-8 part, Cortex Cinnamomi 0.1-1 part.On this basis, each active drug is even more ideal in following scope to be equivalent to the used medical material weight ratio of its extraction with the component extract: 2 parts of Cortex Phellodendris, 2 parts of the Rhizoma Anemarrhenaes, 0.3 part of Cortex Cinnamomi.
In pharmaceutical composition of the present invention, contain following one or more effective ingredient: Cortex Phellodendri total alkaloids content 〉=10%[berberine (Berberine) or berberine hydrochloride (Berberine Hydrochloride) content 〉=1% wherein; Total alkaloid content is with thin layer spectrophotometry (time precious traditional Chinese medical science traditional Chinese medicines, 1999 the 8th phases); Berberine or content of berberine hydrochloride high effective liquid chromatography for measuring (PLA's Acta Pharmaceutica Sinica, 2004 the 3rd phases)]; Rhizoma Anemarrhenae total glycosides content 〉=8%[is 1-timosaponin A-1 3 (Timosaponin A3) content 〉=0.3% wherein; Chinonin (Mangiferin) content 〉=0.1%; Rhizoma Anemarrhenae total glycosides, 1-timosaponin A-1 3 and Chinonin content are all used high effective liquid chromatography for measuring (Chinese Pharmacopoeia version in 2005)]; Cortex Cinnamomi volatile oil component content 〉=0.1%[is cinnamic aldehyde (cinnamicaldehyde) content 〉=0.05% wherein; Total volatile oil and cinnamic aldehyde content are all used gas chromatography determination (pharmaceutical analysis magazine, 2000 the 2nd phases)], polyatomic phenol component content 〉=1%[is procyanidin (procyanidins) content 〉=0.05% wherein; The total composition content of polyhydric phenols colorimetric method for determining (food and fermentation industries, 2002 the 3rd phases); Procyanidin content high effective liquid chromatography for measuring (natural drug research and development, 2002 the 4th phases)].
Pharmaceutical composition of the present invention can be made various clinical application thing preparations with suitable pharmaceutical necessities, as tablet, and capsule, drop pill, sustained-release and controlled release preparation, granule, oral liquid, subcutaneous administration and injecting and administering preparations etc.
Pharmaceutical composition of the present invention can prepare by the following method.
The preparation of Cortex Phellodendri extract:
Method 1: get the Cortex Phellodendri medical material, pulverize, extract, filter (or centrifugal) with 50-90% alcohol reflux (or percolation), filtrate (or supernatant) is reclaimed ethanol and is concentrated the back and uses macroporous resin adsorption, water elution impurity, reuse 65-80% ethanol elution, reclaim ethanol, concentrate, be drying to obtain.Total alkaloid content in the extract 〉=50%, wherein berberine or content of berberine hydrochloride 〉=5% (content assaying method is the same).
Method 2: get the Cortex Phellodendri medical material, pulverize, (ethanol: hydrochloric acid=100: 0.5-3) backflow (or percolation) is extracted with ethanol-HYDROCHLORIC ACID MIXED SOLVENT, filter (or centrifugal), filtrate (or supernatant) is transferred PH to 8.5-10 with lime water, filters (or centrifugal), filtrate (or supernatant) adds sodium chloride, transfer PH to 1-2 with hydrochloric acid, sucking filtration is drying to obtain.Total alkaloid content in the extract 〉=50%, wherein berberine or content of berberine hydrochloride 〉=5% (content assaying method is the same).
The preparation of Rhizoma Anemarrhenae extract:
Method 1: get rhizoma ane marrhenae, pulverize, extract, filter (or centrifugal) with 50-90% alcohol reflux (or percolation), filtrate (or supernatant) is reclaimed ethanol and is concentrated the back and uses macroporous resin adsorption, water elution impurity, reuse 65-80% ethanol elution, reclaim ethanol, concentrate, be drying to obtain.Total glycosides content 〉=30% in the extract, 1-timosaponin A-1 3 content 〉=0.5% wherein, Chinonin content 〉=0.2% (content assaying method is the same).
Method 2: get rhizoma ane marrhenae, pulverize, extract with 50-90% alcohol reflux (or percolation), filter (or centrifugal), after filtrate (or supernatant) recovery ethanol also concentrates, use n-butanol extraction, reclaim n-butyl alcohol, the water-soluble back of extractum macroporous resin adsorption, water elution impurity, reuse 65-80% ethanol elution reclaims ethanol, concentrate, be drying to obtain.Total glycosides content 〉=40% in the extract, 1-timosaponin A-1 3 content 〉=0.8% wherein, Chinonin content 〉=0.4% (content assaying method is the same).
The preparation of Cortex Cinnamomi extract:
The extraction of volatile oil composition:
Method 1: get the Cortex Cinnamomi medical material, pulverize, put in the supercritical fluid extraction equipment extraction column, adopt carbon dioxide to extract (pressure 25-35Mpa as supercritical fluid, flow 2.0-3.0L/min, temperature 35-50 ℃), get extractive of volatile oil, wherein cinnamic aldehyde content 〉=5% (content assaying method is the same).
Method 2: get the Cortex Cinnamomi medical material, pulverize, it is moistening to be soaked in water, and puts in the distillator, feeds water vapour, collects condensed distillate, through oil-water separation, gets volatile oil, wherein contains cinnamic aldehyde 〉=1% (content assaying method is the same).
The extraction of polyatomic phenol composition:
Method 1: get the Cortex Cinnamomi medical material, pulverize, extract, filter (or centrifugal) with 50-80% ethanol percolation (or merceration or room temperature dynamic extraction), after filtrate (or supernatant) recovery ethanol also concentrates, use macroporous resin adsorption, water elution impurity, reuse eluent ethyl acetate, reclaim solvent, drying promptly gets the polyhydric phenols extract, wherein procyanidin content 〉=1% (content assaying method is the same).
Method 2: get the Cortex Cinnamomi medical material, pulverize, extract with acetone merceration (or room temperature dynamic extraction), filter, filtrate is reclaimed solvent, with petroleum ether or chloroform extraction defat, the reuse ethyl acetate extraction reclaims solvent, drying, promptly get the polyhydric phenols extract, wherein procyanidin content 〉=1% (content assaying method is the same).
Above-mentioned Cortex Cinnamomi volatile oil extract and polyhydric phenols extract are mixed, promptly get Cortex Cinnamomi active drug component.
It is 2 parts of Cortex Phellodendris to be equivalent to the used medical material weight ratio of its extraction that pharmaceutical composition of the present invention both can extract the back respectively as stated above by Cortex Phellodendri, the Rhizoma Anemarrhenae and Cortex Cinnamomi single medical material, Rhizoma Anemarrhenae 1-8 part, Cortex Cinnamomi 0.1-1 part, or 2 parts of Cortex Phellodendris, 2 parts of the Rhizoma Anemarrhenaes, 0.3 part of compatibility of Cortex Cinnamomi mixes, also can will mix with Cortex Cinnamomi volatile oil and polyhydric phenols extract compatibility again behind Cortex Phellodendri and the Rhizoma Anemarrhenae two flavor medical material united extraction by the following method, or will mix with the Cortex Cinnamomi volatile oil compatibility again behind Cortex Phellodendri, the Rhizoma Anemarrhenae and the Cortex Cinnamomi three flavor medical material united extraction.
Cortex Phellodendri and the Rhizoma Anemarrhenae two flavor medical material united extraction:
Get 2 parts of Cortex Phellodendris, Rhizoma Anemarrhenae 1-8 part, or 2 parts of Cortex Phellodendris, 2 parts of the Rhizoma Anemarrhenaes merge and pulverize, and extract with 50-90% alcohol reflux (or percolation), filter (or centrifugal), filtrate (or supernatant) is reclaimed ethanol, and medicinal liquid adsorbs with low pole or non-polar macroporous resin, water eluting impurity, reuse 60-80% ethanol elution, eluent reclaims ethanol, concentrates, drying promptly gets the extract that contains Cortex Phellodendri total alkaloids and Rhizoma Anemarrhenae total glycosides.Berberine or content of berberine hydrochloride 〉=2% wherein, 1-timosaponin A-1 3 content 〉=0.5%, Chinonin content 〉=0.2% (content assaying method is the same).
This extract mixes with the Cortex Cinnamomi volatile oil and the polyhydric phenols extract compatibility that extract as stated above, promptly can be made into the thin compound of medicine of the present invention.
Cortex Phellodendri, the Rhizoma Anemarrhenae and Cortex Cinnamomi three flavor medical material united extraction:
Get 2 parts of Cortex Phellodendris, Rhizoma Anemarrhenae 1-8 part, Cortex Cinnamomi 0.1-1 part, or 2 parts of Cortex Phellodendris, 2 parts of the Rhizoma Anemarrhenaes, 0.3 part of Cortex Cinnamomi, merge and pulverize, extract, filter (or centrifugal) with 50-90% ethanol percolation (or merceration or room temperature dynamic extraction), filtrate (or supernatant) is reclaimed ethanol, and medicinal liquid adsorbs water eluting impurity with low pole or non-polar macroporous resin, reuse 60-80% ethanol elution, eluent reclaims ethanol, concentrates, drying promptly gets the extract that contains Cortex Phellodendri total alkaloids, Rhizoma Anemarrhenae total glycosides and Cortex Cinnamomi polyhydric phenols.Berberine or content of berberine hydrochloride 〉=1.5% wherein, 1-timosaponin A-1 3 content 〉=0.4%, Chinonin content 〉=0.3%, procyanidin content 〉=0.01% (content assaying method is the same).
This extract mixes with the Cortex Cinnamomi volatile oil compatibility that extracts as stated above, promptly can be made into pharmaceutical composition of the present invention.
Pharmaceutical composition of the present invention is irritated stomach to be given streptozotocin and causes around the diabetes model rat, observe its influence, found that this pharmaceutical composition has following pharmacological action pharmacology indexs such as random blood sugar, fasting glucose, carbohydrate tolerance, body weight, insulin tolerance and C peptides:
● the random blood sugar and the fasting glucose of diabetes rat obviously descend, and have compared significant difference (P＜0.01, P＜0.05) with model group.
● carbohydrate tolerance test shows, diabetes rat before giving sugar and give after the sugar 30,60,90 and the blood glucose during 120min all be starkly lower than model group (p＜0.01).
● the inductive diabetes rat body weight of streptozotocin there is tangible restitution (p＜0.01).
● in insulin tolerance test, diabetes rat all is starkly lower than model group (p＜0.01) in the blood sugar level of each time point.
● the serum C peptide horizontal detection shows, the C peptide level of diabetes rat is apparently higher than model group (P＜0.05), shows that the serum insulin level obviously recovers.
● the twenty-four-hour urine amount of diabetes rat and urine protein content are starkly lower than model group (P＜0.01, P＜0.05).
● the urine inosine of diabetes rat obviously rises, with model group comparing difference remarkable (P＜0.05).
● the renal index of diabetes rat is starkly lower than model group (P＜0.05).
Pharmacological tests shows that pharmaceutical composition of the present invention has significant treatment diabetes and diabetic nephropathy effect.
The specific embodiment
Further specify the present invention by the following examples, but not limited by embodiment.
Embodiment 1
Get 2 parts of Cortex Phellodendris, 2 parts of the Rhizoma Anemarrhenaes, 0.3 part of Cortex Cinnamomi, merge and pulverize, use 70% ethanol percolate extraction, collect percolate, centrifugal, supernatant decompression recycling ethanol, medicinal liquid AB-8 macroporous resin adsorption, water elution impurity with 1.5 column volumes, 70% ethanol elution of 5 column volumes of reuse, the eluent decompression recycling ethanol concentrates, drying promptly gets the extract that contains Cortex Phellodendri total alkaloids, Rhizoma Anemarrhenae total glycosides and Cortex Cinnamomi polyhydric phenols.Wherein content of berberine hydrochloride is greater than 1.5%, and 1-timosaponin A-1 3 content are greater than 0.4%, and Chinonin content is greater than 0.3%, and procyanidin content is greater than 0.01% (content assaying method is the same).
Embodiment 2
Get 0.3 part of Cortex Cinnamomi medical material, pulverize, put in the supercritical fluid extraction equipment extraction column, adopt carbon dioxide to extract (pressure 30Mpa, flow 2.0L/min, 40 ℃ of temperature) as supercritical fluid, get extractive of volatile oil, wherein cinnamic aldehyde content is greater than 5% (content assaying method is the same).
The extract that embodiment 1 is made mixes with the extract compatibility that embodiment 2 makes, and promptly gets pharmaceutical composition of the present invention.
Embodiment 3
Get the SD rat, body weight 200+5g, after adaptability is raised a week, press 55mg/kg lumbar injection streptozotocin, the injection back was detected random blood sugar on the 7th day, carry out random packet according to the random blood sugar level, every group 10, blood sugar level is basicly stable after two weeks, begin the oral pharmaceutical composition of the present invention of difference (2g crude drug/kg) treat, indexs such as random blood sugar that back mensuration is respectively organized around the administration, fasting glucose, carbohydrate tolerance, insulin tolerance, body weight with positive control drug metformin hydrochloride (18mg/kg).The result is as follows:
1, to the influence of random blood sugar
Streptozotocin cause diabetes rat around the Drug therapy after the random blood sugar situation
| Group | Normal thin | Model group | Pharmaceutical composition of the present invention | Metformin |
| Blood glucose (mmol/l) | 5.2±0.18 | 30.75±3.05 | 19.11±3.82** | 12.16±1.17** |
* and model group relatively have utmost point significant difference P＜0.01
The result shows: streptozotocin causes rat random blood sugar level to raise, and has compared utmost point significant difference with normal group; After respectively with pharmaceutical composition of the present invention and the treatment all around of positive control drug metformin hydrochloride, the random blood sugar level descends significantly, has compared utmost point significant difference P＜0.01 with model group.
2, to the influence of fasting glucose
Streptozotocin cause diabetes rat around the Drug therapy after the fasting glucose situation
| Group | Normal group | Model group | Pharmaceutical composition of the present invention | Metformin |
| Blood glucose (mmol/l) | 4.16±0.46 | 17.9±4.79 | 9.33±5.91* | 6.54±1.13** |
* with model group relatively there were significant differences P＜0.05
* and model group relatively have utmost point significant difference P＜0.01
The result shows: streptozotocin causes the rat fasting blood-glucose level to raise, and has compared utmost point significant difference with normal group; After around respectively with the treatment of pharmaceutical composition of the present invention and positive control drug metformin hydrochloride, fasting blood glucose level descends significantly, compares with model group that there were significant differences (P＜0.05, P＜0.01).
3, to the influence of carbohydrate tolerance
Streptozotocin cause diabetes rat around the Drug therapy after the carbohydrate tolerance situation
* and model group relatively have utmost point significant difference P＜0.01
The result shows: each organized rat limosis 8 hours, and give glucose behind the survey blood glucose and irritate stomach, dosage 2g/kg, blood glucose is surveyed in the different time points blood sampling.Pharmaceutical composition of the present invention and positive control drug metformin are before giving sugar and all be starkly lower than model group P＜0.01 for the blood glucose of sugar back 30,60,90,120min.
4, insulin tolerance experiment
Streptozotocin cause diabetes rat around the Drug therapy after the insulin tolerance situation
* and model group relatively have utmost point significant difference P＜0.01
The result shows: blood sugar level occurred descending at 30 minutes after model group gave insulin, changed not obvious between 60-120 minute.Each time point blood sugar level of treatment group pharmaceutical composition of the present invention and positive control drug metformin is starkly lower than model group, and utmost point significant difference P＜0.01 is arranged, and treatment group blood sugar level is gradually steady between 2-4 hour, and this performance to normal group is similar.
5, to the influence of body weight
Streptozotocin cause diabetes rat around the Drug therapy after the body weight situation
| Group | Normal group | Model group | Pharmaceutical composition of the present invention | Metformin 18mg/kg |
| Body weight (g) | 456±-35.1 | 223.75±8.26 | 316±57.2** | 385±40.3** |
* and model group relatively have utmost point significant difference P＜0.01
The result shows: streptozotocin causes the rat limosis weight loss, has compared utmost point significant difference with normal group; After with pharmaceutical composition of the present invention and the treatment all around of positive control drug metformin hydrochloride, body weight is obviously recovered (P＜0.01) than model group.
Claims (8)
1, a kind of diabetes or diabetic nephropathy drugs compositions of being used for the treatment of, by the Chinese medicine Cortex Phellodendri, the Rhizoma Anemarrhenae and cinnamomic extract are that active drug is formed with component compatibility, each active drug with the component extract to be equivalent to the used medical material weight ratio of its extraction is: 2 parts of Cortex Phellodendris, Rhizoma Anemarrhenae 1-8 part, Cortex Cinnamomi 0.1-1 part.
2, treatment diabetes according to claim 1 or diabetic nephropathy drugs compositions is characterized in that described each active drug with the component extract to be equivalent to the used medical material weight ratio of its extraction is: 2 parts of Cortex Phellodendris, 2 parts of the Rhizoma Anemarrhenaes, 0.3 part of Cortex Cinnamomi.
3, according to claim 1 and/or 2 described treatment diabetes or diabetic nephropathy drugs compositionss, it is characterized in that wherein containing following one or more effective ingredient: Cortex Phellodendri total alkaloids content 〉=10%[berberine (Berberine) or berberine hydrochloride (Berberine Hydrochloride) content 〉=1% wherein]; Rhizoma Anemarrhenae total glycosides content 〉=8%[is 1-timosaponin A-1 3 (TimosaponinA3) content 〉=0.3% wherein; Chinonin (Mangiferin) content 〉=0.1%]; Cortex Cinnamomi volatile oil content 〉=0.1%[is cinnamic aldehyde (cinnamicaldehyde) content 〉=0.05% wherein], polyatomic phenol component content 〉=1%[is procyanidin (procyanidins) content 〉=0.05% wherein].
4, as claim 1,2 or 3 described treatment diabetes or diabetic nephropathy drugs preparation of compositions method, it is characterized in that extracting the back respectively by Cortex Phellodendri, the Rhizoma Anemarrhenae and Cortex Cinnamomi single medical material is 2 parts of Cortex Phellodendris to be equivalent to the used medical material weight ratio of its extraction, Rhizoma Anemarrhenae 1-8 part, Cortex Cinnamomi 0.1-1 part, or 2 parts of Cortex Phellodendris, 2 parts of the Rhizoma Anemarrhenaes, 0.3 part of compatibility of Cortex Cinnamomi forms; Or will form with Cortex Cinnamomi volatile oil and polyatomic phenol extract compatibility again behind Cortex Phellodendri and the Rhizoma Anemarrhenae two flavor medical material united extraction; Or will form with the Cortex Cinnamomi volatile oil compatibility again behind Cortex Phellodendri, the Rhizoma Anemarrhenae and the Cortex Cinnamomi three flavor medical material united extraction.
5, treatment diabetes as claimed in claim 4 or diabetic nephropathy drugs preparation of compositions method, it is characterized in that Cortex Phellodendri and the Rhizoma Anemarrhenae two flavor medical material united extraction: get 2 parts of Cortex Phellodendris, Rhizoma Anemarrhenae 1-8 part, or 2 parts of Cortex Phellodendris, 2 parts of the Rhizoma Anemarrhenaes, merge and pulverize, extract, filter (or centrifugal) with 50-90% alcohol reflux (or percolation), filtrate (or supernatant) is reclaimed ethanol, the medicinal liquid macroporous resin adsorption, water eluting impurity, reuse 60-80% ethanol elution, eluent reclaims ethanol, concentrate, drying promptly gets the extract that contains Cortex Phellodendri alkaloids composition and Rhizoma Anemarrhenae glycoside composition; This extract mixes with Cortex Cinnamomi volatile oil and polyatomic phenol extract compatibility, promptly can be made into pharmaceutical composition of the present invention.
6, treatment diabetes as claimed in claim 4 or diabetic nephropathy drugs preparation of compositions method, it is characterized in that Cortex Phellodendri, the Rhizoma Anemarrhenae and Cortex Cinnamomi three flavor medical material united extraction: get 2 parts of Cortex Phellodendris, Rhizoma Anemarrhenae 1-8 part, Cortex Cinnamomi 0.1-1 part, or 2 parts of Cortex Phellodendris, 2 parts of the Rhizoma Anemarrhenaes, 0.3 part of Cortex Cinnamomi, merge and pulverize, extract filtration or centrifugal with 50-90% ethanol merceration or percolation, filtrate or supernatant reclaim ethanol, the medicinal liquid macroporous resin adsorption, water eluting impurity, reuse 60-80% ethanol elution, eluent reclaims ethanol, concentrate, drying promptly gets and contains the Cortex Phellodendri alkaloids, the extract of Rhizoma Anemarrhenae glycoside and Cortex Cinnamomi polyatomic phenol composition; This extract mixes with Cortex Cinnamomi volatile oil extract compatibility, promptly can be made into pharmaceutical composition of the present invention.
7, according to claim 1,2,3 or 4 described treatment diabetes or diabetic nephropathy drugs compositionss, it is characterized in that said composition can with as tablet, capsule, drop pill, sustained-release and controlled release preparation, the pharmaceutical necessities of granule, oral liquid, subcutaneous administration and injecting medicine-feeding form is mixed with corresponding pharmaceutical preparation.
8, the purposes of treatment diabetes as claimed in claim 1 or diabetic nephropathy drugs compositions is used in preparation treatment diabetes and diabetic nephropathy drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101107632A CN100506259C (en) | 2005-11-25 | 2005-11-25 | Medicine composition for treating diabetes or diabetes kidney-disease, and preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101107632A CN100506259C (en) | 2005-11-25 | 2005-11-25 | Medicine composition for treating diabetes or diabetes kidney-disease, and preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1814149A true CN1814149A (en) | 2006-08-09 |
| CN100506259C CN100506259C (en) | 2009-07-01 |
Family
ID=36906581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101107632A Active CN100506259C (en) | 2005-11-25 | 2005-11-25 | Medicine composition for treating diabetes or diabetes kidney-disease, and preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100506259C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101229316B (en) * | 2008-01-31 | 2010-08-25 | 广东药学院 | Rhizoma anemarrhenae extrac |
| CN101332228B (en) * | 2007-06-28 | 2011-06-01 | 上海幼虎生物医药有限公司 | Traditional Chinese medicine composition for treating disease with common pathogenic basis of 'insulin resistance', such as type II diabetic |
| CN107158016A (en) * | 2017-06-09 | 2017-09-15 | 徐州医科大学 | The application of timosaponin and its aglycon in prevention and treatment early diabetic nephropathy medicine is prepared |
| CN108743783A (en) * | 2018-08-29 | 2018-11-06 | 齐爱萍 | A kind of Chinese medicine for treating diabetes |
| CN110215454A (en) * | 2018-03-01 | 2019-09-10 | 上海中医药大学 | A kind of composition and its application with hypoglycemic lipid-lowering effect |
| CN113368183A (en) * | 2021-07-06 | 2021-09-10 | 天津中医药大学 | Traditional Chinese medicine composition for nourishing yin and clearing heat and application thereof |
| CN116139216A (en) * | 2022-11-09 | 2023-05-23 | 陕西含光生物科技有限公司 | Compound traditional Chinese medicine and extract thereof and application of compound traditional Chinese medicine in treatment of glycolipid metabolic diseases |
-
2005
- 2005-11-25 CN CNB2005101107632A patent/CN100506259C/en active Active
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101332228B (en) * | 2007-06-28 | 2011-06-01 | 上海幼虎生物医药有限公司 | Traditional Chinese medicine composition for treating disease with common pathogenic basis of 'insulin resistance', such as type II diabetic |
| CN101229316B (en) * | 2008-01-31 | 2010-08-25 | 广东药学院 | Rhizoma anemarrhenae extrac |
| CN107158016A (en) * | 2017-06-09 | 2017-09-15 | 徐州医科大学 | The application of timosaponin and its aglycon in prevention and treatment early diabetic nephropathy medicine is prepared |
| CN110215454A (en) * | 2018-03-01 | 2019-09-10 | 上海中医药大学 | A kind of composition and its application with hypoglycemic lipid-lowering effect |
| CN110215454B (en) * | 2018-03-01 | 2021-10-29 | 上海中医药大学 | Composition with effects of reducing blood sugar and blood fat and application thereof |
| CN108743783A (en) * | 2018-08-29 | 2018-11-06 | 齐爱萍 | A kind of Chinese medicine for treating diabetes |
| CN113368183A (en) * | 2021-07-06 | 2021-09-10 | 天津中医药大学 | Traditional Chinese medicine composition for nourishing yin and clearing heat and application thereof |
| CN116139216A (en) * | 2022-11-09 | 2023-05-23 | 陕西含光生物科技有限公司 | Compound traditional Chinese medicine and extract thereof and application of compound traditional Chinese medicine in treatment of glycolipid metabolic diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100506259C (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100506259C (en) | Medicine composition for treating diabetes or diabetes kidney-disease, and preparing method | |
| CN1965885B (en) | Application of total flavones of chickpea in preparation of medicament for treating diabetes | |
| CN100345558C (en) | Extract product of general flavone of kudzuvine root, preparation method and application | |
| CN102512482A (en) | Euonymus alatus extract, blood-sugar-reducing activity thereof and application of euonymus alatus extract to preparation of products for reducing blood sugar | |
| CN101862346B (en) | Hypoglycemic application of gingseng acidic polysaccharide | |
| CN101032537A (en) | Gynura procumbens (Lour.) Merr. Flavonoid substances preparing method and the application | |
| CN1194702C (en) | Herba-Epimedii extract for treating prostatic hyerplasia and use in preparing medicine | |
| CN101816719B (en) | Peach blossom or peach leaf general flavone and application thereof in preparing medicines or health care products for lowering blood sugar and fat and preventing and/or treating diabetes and complications | |
| CN103432420B (en) | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method | |
| CN100444849C (en) | New use of tribulus terrestris extraction | |
| CN1973853A (en) | Hemostatic and analgetic medicine composition and its prepn process | |
| CN1810265A (en) | Total sennoside extract for treating constipation and its extraction process | |
| CN1193766C (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
| CN101601760B (en) | Application of murraya jasminorage leaf total flavonoids in preparing medicaments for treating diabetes | |
| CN100355440C (en) | Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method | |
| CN100411653C (en) | Chinese medicine composition for treating diabetes mellitus | |
| CN101249129B (en) | Chinese medicine extract combination and medicine use thereof | |
| CN1692922A (en) | Medicine composite used for lowering blood-sugar, prepn. method and use thereof | |
| CN1977888B (en) | Medicinal composition of baicalin, ganoderma lucidum and salvia miltrorrhiza | |
| CN1181836C (en) | Chinese medicine composition for treating diabetes and its preparing process | |
| CN100484543C (en) | Medicament composition for treating hepatitis, prepartion method and use | |
| CN1475222A (en) | Vine leaf extract and its preparation process | |
| CN1575803A (en) | Application method of Aloe vera L. extract in preventing and curing diabetes | |
| CN1254260C (en) | Medicine composition containing epimedium extract | |
| CN100588411C (en) | Medicine composition containing franchet groundcherry steride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |